Radiologic responses in cynomolgus macaques for assessing tuberculosis chemotherapy regimens

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 9, 2013, Pages 4237-4244

  Lin, Philana Ling ^a   Coleman, Teresa ^b   Carney, Jonathan P J ^b   Lopresti, Brian J ^b   Tomko, Jaime ^c   Fillmore, Dan ^c   Dartois, Veronique ^d   Scanga, Charles ^c,e   Frye, L James ^e   Janssen, Christopher ^e   Klein, Edwin ^e   Barry Iii, Clifton E ^f   Flynnc, Jo Anne L ^e  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; FLUORODEOXYGLUCOSE F 18; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; AUTOPSY; BACTERIAL GROWTH; BACTERIAL LOAD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; LUNG GRANULOMA; LUNG LAVAGE; LYMPH NODE; MACACA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 84882427707     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00277-13     Document Type: Article

References (35)

1. Wallis RS, Perkins MD, Phillips M, Joloba M, Namale A, Johnson JL, Whalen CC, Teixeira L, Demchuk B, Dietze R, Mugerwa RD, Eisenach K, Ellner JJ. 2000. Predicting the outcome of therapy for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 161(4 Pt 1):1076-1080.
2. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. 2010. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect. Dis. 10:387-394.
3. Hamilton CD, Stout JE, Goodman PC, Mosher A, Menzies R, Schluger NW, Khan A, Johnson JL, Vernon AN. 2008. The value of end-oftreatment chest radiograph in predicting pulmonary tuberculosis relapse. Int. J. Tuberc. Lung Dis. 12:1059-1064.
4. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, Noma S. 1993. Pulmonary tuberculosis: CT findings-early active disease and sequential change with antituberculous therapy. Radiology 186:653-660.
5. Jeong YJ, Lee KS. 2008. Pulmonary tuberculosis: up-to-date imaging and management. AJR Am. J. Roentgenol. 191:834-844.
6. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, Klein E, Barry CE, III, Flynn JL. 2012. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc. Natl. Acad. Sci. U. S. A. 109:14188-14193.
7. de Prost N, Tucci MR, Melo MF. 2010. Assessment of lung inflammation with 18F-FDG PET during acute lung injury. AJR Am. J. Roentgenol. 195: 292-300.
8. Defawe OD, Hustinx R, Defraigne JO, Limet R, Sakalihasan N. 2005. Distribution of F-18 fluorodeoxyglucose (F-18 FDG) in abdominal aortic aneurysm: high accumulation in macrophages seen on PET imaging and immunohistology. Clin. Nucl. Med. 30:340-341.
9. Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, Sato N, Konishi J. 2002. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J. Nucl. Med. 43:658-663.
10. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, Zhuang H. 2002. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin. Nucl. Med. 32:293-321.
11. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. 2000. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117-121.
12. Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, Shim YM, Yi CA, Kim HY, Chung MJ. 2007. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer 109:1068-1077.
13. Yago Y, Yukihiro M, Kuroki H, Katsuragawa Y, Kubota K. 2005. Cold tuberculous abscess identified by FDG PET. Ann. Nucl. Med. 19:515-518.
14. Sathekge M, Maes A, Kgomo M, Stolt A, Van de Wiele C. 2011. Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIVassociated tuberculosis. J. Nucl. Med. 52:880-885.
15. Tian G, Xiao Y, Chen B, Xia J, Guan H, Deng Q. 2010. FDG PET/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis. Acta Radiol. 51:1002-1006.
16. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, Grenier G, Fior R, Desarnaud S, Doucet-Populaire F, Boue F. 2012. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int. J. Tuberc. Lung Dis. 16:1180-1185.
17. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluorodeoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
18. Herschman HR. 2003. Micro-PET imaging and small animal models of disease. Curr. Opin. Immunol. 15:378-384.
19. Via LE, Schimel D, Weiner DM, Dartois V, Dayao E, Cai Y, Yoon YS, Dreher MR, Kastenmayer RJ, Laymon CM, Carney JE, Flynn JL, Herscovitch P, Barry CE, III. 2012. Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [(18)F]2-fluorodeoxy-D-glucose positron emission tomography and computed tomography. Antimicrob. Agents Chemother. 56:4391-4402.
20. Lin PL, Rodgers M, Smith L, Bigbee M, Myers A, Bigbee C, Chiosea I, Capuano SV, Fuhrman C, Klein E, Flynn JL. 2009. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model. Infect. Immun. 77:4631-4642.
21. McLeay SC, Morrish GA, Kirkpatrick CM, Green BB. 2012. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin. Pharmacokinet. 51:319-330.
22. Capuano SV, III, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, Bissel S, Fuhrman C, Klein E, Flynn JL. 2003. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71:5831-5844.
23. Rumbolt Z, Huda W, All JW. 2009. Review of portable CT with assessment of a dedicated head CT scanner. Am. J. Neuroradiol. 30:1630-1636.
24. Lin PL, Pawar S, Myers A, Pegu A, Fuhrman C, Reinhart TA, Capuano SV, Klein E, Flynn JL. 2006. Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. Infect. Immun. 74:3790-3803.
25. Canetti G. 1955. The tubercle bacillus. Springer Publishing Co, Inc, New York, NY.
26. Leong FJ, Eum SK, Via L, Barry CE, III. 2011. Pathology of tuberculosis in human lung. In Leong FJ, Dartois V, Dick T (ed), A color atlas of comparative pathology of pulmonary tuberculosis. CRC Press, Boca Raton, FL.
27. Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
28. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518.
29. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
30. An N, Song Y, Zhang X, Ci X, Li H, Cao Y, Zhang M, Cui J, Deng X. 2008. Pretreatment of mice with rifampicin prolongs survival of endotoxic shock by modulating the levels of inflammatory cytokines. Immunopharmacol. Immunotoxicol. 30:437-446.
31. Nau R, Wellmer A, Soto A, Koch K, Schneider O, Schmidt H, Gerber J, Michel U, Bruck W. 1999. Rifampin reduces early mortality in experimental Streptococcus pneumoniae meningitis. J. Infect. Dis. 179:1557-1560.
32. Lee SW, Lee SH, Yim JJ. 2012. Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. Infection 40: 431-435.
33. Dyrhol-Riise AM, Gran G, Wentzel-Larsen T, Blomberg B, Haanshuus CG, Morkve O. 2010. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold in-tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect. Dis. 10:57. doi:10.1186/1471-2334- 10-57.
34. Wilkinson KA, Kon OM, Newton SM, Meintjes G, Davidson RN, Pasvol G, Wilkinson RJ. 2006. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J. Infect. Dis. 193:354-359.
35. Lee SW, Lee CT, Yim JJ. 2010. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect. Dis. 10:300. doi:10.1186/1471-2334-10-300.